TALAPRO-3: Talazoparib + Enzalutamide + ADT in HRR-Altered mCSPC

Authored by Natalia Gandur, published on 2026-07-05 14:48:29.0

The algorithm is broadly aligned with current mCSPC practice in emphasizing ADT as backbone therapy, recommending treatment intensification, and incorporating germline/somatic testing to guide therapy selection. The main uncertainty is the role of talazoparib + enzalutamide + ADT specifically in the mCSPC setting, which depends on maturation of TALAPRO-3 results and local regulatory/guideline adoption. Monitoring and progression reassessment steps reflect standard oncology care pathways.

  1. Confirm HRR-altered mCSPC treatment context
    • 1. Confirm mCSPC
      Metastatic castration-sensitive prostate cancer
      • 2. Start / continue ADT
        Androgen deprivation therapy
        • 3. Obtain HRR testing
          Germline and/or somatic testing for homologous recombination repair (HRR) alterations. TALAPRO-3 HRR genes: ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C. Testing nuance: cfDNA testing may miss clinically relevant alterations, particularly BRCA2 homozygous deletions, when tumor fraction is low. Consider tissue-based testing when cfDNA tumor fraction is <10%, or when cfDNA is negative/indeterminate but clinical suspicion remains high.
          • 4. HRR alteration present?
            • Yes
              • 5. Assess suitability for talazoparib + enzalutamide + ADT
                Performance status / functional status; Hematologic reserve (CBC, anemia, platelet count); Comorbidities and organ function (hepatic, renal); CNS history / seizure risk; Drug interactions and concomitant medications; Access / regulatory status / reimbursement; Ability to adhere and undergo monitoring
                • 6. Eligible and feasible?
                  • Yes
                    • Consider TALAPRO-3–based strategy: talazoparib + enzalutamide + ADT
                      For HRR-altered mCSPC where supported by trial data, regulatory approval/access, and expert consensus. Talazoparib 0.5 mg PO once daily + enzalutamide 160 mg PO once daily + ongoing ADT. Consider renal function, baseline marrow reserve, drug interactions, and protocol / prescribing information / local guidance for dose adjustment.
                      • 7. Monitor during therapy
                        Suggested early monitoring: - Baseline CBC with differential/platelets, renal function, liver tests, blood pressure, symptoms, falls risk, concomitant medications, and functional status. - In patients with preexisting anemia, consider baseline vitamin B12, folate, and iron studies before starting talazoparib. Early follow-up: - Clinical review and CBC at approximately weeks 2, 4, 8, and 12, then monthly or as clinically indicated. - Track hemoglobin trajectory closely during the first 3 to 4 months, when clinically significant talazoparib-associated anemia may emerge early. Monitor: - Hemoglobin decline - Symptoms of anemia - Transfusion need - Neutropenia - Thrombocytopenia - Fatigue - Nausea - Blood pressure - Dizziness/falls - Adherence - PSA trend - Imaging response - Quality of life Patients with a rapid early hemoglobin decline may warrant earlier reassessment, supportive care, evaluation for reversible contributors, and consideration of dose modification before severe anemia develops.
                        • Anemia and myelosuppression are key toxicities, particularly with talazoparib-based therapy.
                          Anemia and myelosuppression are key implementation issues with talazoparib-based therapy. Baseline risk assessment:In patients with preexisting anemia, consider checking vitamin B12, folate, and iron studies before initiating talazoparib. Correct clinically relevant deficiencies when feasible, since nutritional deficiency may worsen treatment-associated anemia. If significant anemia develops: Assess symptoms, hemoglobin trajectory, transfusion need, bleeding, renal function, inflammation, marrow reserve, and disease status. If not already checked, evaluate reversible contributors such as vitamin B12, folate, and iron deficiency. Provide supportive care and transfusion when clinically indicated. For grade 3-4 anemia or hemoglobin <8 g/dL: Hold talazoparib. Monitor CBC closely until recovery. Resume talazoparib at a reduced dose when appropriate. Talazoparib dose-reduction sequence with enzalutamide:0.5 mg daily → 0.35 mg daily → 0.25 mg daily → 0.1 mg daily. Dose reduction is recommended once grade 3-4 anemia develops. Expert implementation caveat:If a patient appears likely to develop grade 3 anemia based on the rate of hemoglobin decline during the first 3 to 4 months, a preemptive talazoparib dose reduction may be considered before grade 3 anemia occurs, particularly if the goal is to prevent severe anemia while maintaining therapy. Discontinue talazoparib if more than 3 dose reductions are required or if MDS/AML is confirmed.
                          • 8. At progression
                            Confirm castration-resistant transition, including castrate testosterone level. Reassess disease state, symptoms, imaging, PSA kinetics, prior PARP exposure, prior ARPI exposure, chemotherapy suitability, radioligand therapy eligibility, molecular profile, clinical trials, and supportive care needs.
                            • Clinical caveats / Key points
                              Key takeaways TALAPRO-3 supports talazoparib + enzalutamide + ADT as an emerging strategy for HRR-altered mCSPC. HRR testing should be performed early in metastatic prostate cancer to guide treatment selection and sequencing. TALAPRO-3 included ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C. cfDNA testing may miss clinically relevant alterations when tumor fraction is low; consider tissue testing when cfDNA tumor fraction is <10% or results are negative/indeterminate despite clinical suspicion. Hematologic toxicity, especially anemia and myelosuppression, is the key implementation issue; early CBC monitoring and proactive management are essential. Additional anemia management caveats: In patients with preexisting anemia, consider baseline vitamin B12, folate, and iron studies before starting talazoparib. Correct reversible nutritional deficiencies when feasible. Clinically significant anemia may occur early; monitor hemoglobin trajectory closely during the first 3 to 4 months. Dose reduction is recommended for grade 3-4 anemia. Preemptive talazoparib dose reduction may be considered if early hemoglobin decline suggests the patient is likely to develop grade 3 anemia. These anemia-management considerations are expert implementation caveats and should be individualized based on symptoms, disease burden, marrow reserve, treatment urgency, and patient goals.
                  • No
                    • Use standard ARPI-based mCSPC pathway
                      Or other appropriate intensification strategy based on patient, disease, and access factors
                      • 8. At progression
                        Confirm castration-resistant transition, including castrate testosterone level. Reassess disease state, symptoms, imaging, PSA kinetics, prior PARP exposure, prior ARPI exposure, chemotherapy suitability, radioligand therapy eligibility, molecular profile, clinical trials, and supportive care needs.
                        • Clinical caveats / Key points
                          Key takeaways TALAPRO-3 supports talazoparib + enzalutamide + ADT as an emerging strategy for HRR-altered mCSPC. HRR testing should be performed early in metastatic prostate cancer to guide treatment selection and sequencing. TALAPRO-3 included ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C. cfDNA testing may miss clinically relevant alterations when tumor fraction is low; consider tissue testing when cfDNA tumor fraction is <10% or results are negative/indeterminate despite clinical suspicion. Hematologic toxicity, especially anemia and myelosuppression, is the key implementation issue; early CBC monitoring and proactive management are essential. Additional anemia management caveats: In patients with preexisting anemia, consider baseline vitamin B12, folate, and iron studies before starting talazoparib. Correct reversible nutritional deficiencies when feasible. Clinically significant anemia may occur early; monitor hemoglobin trajectory closely during the first 3 to 4 months. Dose reduction is recommended for grade 3-4 anemia. Preemptive talazoparib dose reduction may be considered if early hemoglobin decline suggests the patient is likely to develop grade 3 anemia. These anemia-management considerations are expert implementation caveats and should be individualized based on symptoms, disease burden, marrow reserve, treatment urgency, and patient goals.
            • No / Unknown
              • Follow standard mCSPC treatment pathway
                Use guideline-recommended ARPI-based or other standard intensification strategies. Jump to: Metastatic Castration-Resistant Prostate Cancer After Prior ARPI: Choosing the Next Treatment Therapeutic Sequencing in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
tosprivacyTALZENNA (talazoparib) prescribing information. Pfizer; current label.